Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

27.30 +1.04 (+3.96%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

19 20 Next >

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 06, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.

September 05, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

September 05, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Where Apellis Pharmaceuticals Stands With Analysts ↗

August 24, 2023

Via Benzinga

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Near the Top of Equities by Percentage Gain on 8/23

August 23, 2023

Via Investor Brand Network

ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

September 04, 2023

WHY: NEW YORK, NY - (NewMediaWire) - September 04, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...

Via TheNewswire.com

Topics Lawsuit

ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

September 04, 2023

Via NewMediaWire

Topics Lawsuit

ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

September 02, 2023

WHY: NEW YORK, NY - (NewMediaWire) - September 02, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...

Via TheNewswire.com

Topics Lawsuit

ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

September 02, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm

September 01, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

September 01, 2023

Via ACCESSWIRE

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – APLS

August 30, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 30, 2023

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

August 30, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗

August 29, 2023

Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and

Via Benzinga

Catalent (CTLT) Stock Gains on Elliott Deal ↗

August 29, 2023

Catalent (CTLT) stock is getting a boost on Tuesday after the company reached an agreement with Elliott Investment Management.

Via InvestorPlace

Apellis Layoffs 2023: What to Know About the Latest APLS Job Cuts ↗

August 29, 2023

Apellis Pharmaceuticals (APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.

Via InvestorPlace

Topics Workforce

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

August 29, 2023

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.

August 29, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

August 28, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm

August 27, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

August 27, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS

August 26, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗

August 25, 2023

Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...

Via Benzinga

APLS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Apellis Class Action Lawsuit

August 24, 2023

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

3 Very Oversold Pharma Stocks to Buy Right Now ↗

August 24, 2023

Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.

Via InvestorPlace

Apellis Pharma's Newly Launched Eye Drug Set For Resilient Performance, Syfovre Update Sparks Optimism ↗

August 23, 2023

HC Wainwright says the relative lack of new cases is a positive and should jumpstart Apellis Pharmaceuticals Inc (NASDAQ: APLS) Syfovre,

Via Benzinga

S&P 500 Gains 1%; Analog Devices Posts Downbeat Results ↗

August 23, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Wednesday. The Dow traded up 0.51% to 34,462.61 while the NASDAQ rose 1.60% to 13,722.24....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 23, 2023

Via Benzinga

Why Grab Holdings Are Trading Higher By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

August 23, 2023

Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a loss for the second quarter.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.